Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting.
The Combined Shareholders' Meeting was held on Thursday May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.
Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the Combined Shareholders' Meeting.
All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 30th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.
Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2021 Universal Registration Document (Part 3.5.1, pages 153 and seq.).
Information on the results of the votes is detailed below:
- Total number of shares composing the share capital: 40 873 551
- Total number of shares with voting rights: 40 802 918
| Ordinary part | Extraordinary part | |||||
Shareholders | Shares | Votes | Shareholders | Shares | Votes | ||
Shareholders present | 1 | 50 | 50 | 1 | 50 | 50 | |
Proxy to third parties | 0 | 0 | 0 | 0 | 0 | 0 | |
Proxy to the Chairman | 119 | 122 188 | 153 298 | 119 | 122 188 | 153 298 | |
Mail votes | 87 | 27 741 130 | 39 165 996 | 87 | 27 741 130 | 39 165 996 | |
TOTAL | 207 | 27 863 368 | 39 319 344 | 207 | 27 863 368 | 39 319 344 | |
Quorum | 68,287% | 68,287% |
Resolutions | State of adoption | Number of represented shares | Proportion of represented share capital (%) | Total number of votes cast | For | Against | Abstention | |||
Number of votes | in % of votes cast | Number of votes | in % of votes cast | Number of votes | in % of the total voting rights | |||||
Resolution 1 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
Resolution 2 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
Resolution 3 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
Resolution 4 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
Resolution 5 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
Resolution 6 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 36 715 609 | 93,38% | 2 602 905 | 6,62% | 830 | - |
Resolution 7 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 36 715 574 | 93,38% | 2 602 940 | 6,62% | 830 | - |
Resolution 8 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 505 | 38 457 624 | 97,81% | 860 881 | 2,19% | 839 | - |
Resolution 9 - OGM | Adopted | 27 863 368 | 68,169% | 38 699 850 | 38 597 606 | 99,74% | 102 244 | 0,26% | 619 494 | - |
Resolution 10 - OGM | Adopted | 27 863 368 | 68,169% | 38 699 850 | 38 597 606 | 99,74% | 102 244 | 0,26% | 619 494 | - |
Resolution 11 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 38 674 432 | 98,36% | 644 082 | 1,64% | 830 | - |
Resolution 12 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 234 | 39 317 709 | > 99,99% | 525 | < 0,01% | 1 110 | - |
Resolution 13 - OGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 38 598 105 | 98,17% | 719 489 | 1,83% | 1 750 | - |
Resolution 14 - OGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 38 698 105 | 98,42% | 619 489 | 1,58% | 1 750 | - |
Resolution 15 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 37 954 167 | 96,53% | 1 363 427 | 3,47% | 1 750 | - |
Resolution 16 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 37 954 242 | 96,53% | 1 363 352 | 3,47% | 1 750 | - |
Resolution 17 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 534 | 39 317 009 | > 99,99% | 525 | < 0,01% | 1 810 | - |
Resolution 18 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 39 316 769 | > 99,99% | 825 | < 0,01% | 1 750 | - |
Resolution 19 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 37 080 780 | 94,31% | 2 238 399 | 5,69% | 165 | - |
Resolution 20 - EGM | Adopted | 27 863 368 |
By: GlobeNewswire
- 20 May 2022
Return to news
Upcoming Life Sciences Events
|